NuCana (NCNA) Other financing activities (2018 - 2024)

NuCana (NCNA) reported Other financing activities of $9095.1 for Q3 2024, up 259.01% on a YoY basis from $2533.4 in Q4 2023, and up 340.19% sequentially from -$3786.7 in Q2 2024.

NuCana (NCNA) Other financing activities (2018 - 2024) Analysis & Trends

NuCana (NCNA) has 4 years of Other financing activities data on file, last reported at $9095.1 in Q3 2024.

  • For the quarter ending Q3 2024, Other financing activities rose 259.01% year-over-year to $9095.1; the trailing twelve-month figure through Dec 2025 stood at $9095.1 (changed 0.21% YoY), and the FY2025 full-year result was $5.8 million, up 65266.11% from the prior year.
  • Other financing activities advanced to $9095.1 in Q3 2024, from -$3786.7 in the prior quarter.
  • In the past five years, Other financing activities ranged from a high of $9095.1 in Q3 2024 to a low of -$3786.7 in Q2 2024.
Generated on {Timestamp} © BusinessQuant.com
Generated on {Timestamp} Powered by BusinessQuant Logo

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Oculis Holding AG 68,785.72 Bn 68,785.72 Bn -
2 Nanobiotix 1,895.57 Bn 1,895.51 Bn -
3 BeOne Medicines 471.35 Bn 466.56 Bn 1.35 Bn
4 NuCana 279.75 Bn 279.75 Bn -
5 Vertex Pharmaceuticals 120.24 Bn 113.00 Bn 2.59 Bn
6 Regeneron Pharmaceuticals 67.80 Bn 59.04 Bn 3.31 Bn
7 Belite Bio 62.51 Bn 62.51 Bn -
8 Argenx Se 57.38 Bn 57.38 Bn 1.41 Bn
9 Revolution Medicines 37.78 Bn 37.78 Bn -
10 Alnylam Pharmaceuticals 35.71 Bn 32.70 Bn 959.66 Mn

Historic Data

Download Data
DateValue
Sep 30, 2024 9,095.10
Sep 30, 2024 9,095.10
Jun 30, 2024 -3,786.66
Jun 30, 2024 -3,786.66
Mar 31, 2024 3,805.55
Mar 31, 2024 3,805.55
Dec 31, 2023 1,241.15
Dec 31, 2023 1,241.15
Sep 30, 2023 2,533.37
Sep 30, 2023 2,533.37
Mar 31, 2023 1,215.51
Mar 31, 2023 1,215.51
Dec 31, 2019 10,285.80
Dec 31, 2019 10,285.80
Sep 30, 2019 38,230.86
Sep 30, 2019 38,230.86
Dec 31, 2018 32,169.18
Dec 31, 2018 32,169.18